These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38536949)

  • 61. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
    Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
    Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
    [TBL] [Abstract][Full Text] [Related]  

  • 62. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
    Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeted polymeric nanoparticles for drug delivery to hypoxic, triple-negative breast tumors.
    Mamnoon B; Loganathan J; Confeld MI; De Fonseka N; Feng L; Froberg J; Choi Y; Tuvin DM; Sathish V; Mallik S
    ACS Appl Bio Mater; 2021 Feb; 4(2):1450-1460. PubMed ID: 33954285
    [TBL] [Abstract][Full Text] [Related]  

  • 64. In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.
    Pérez-Peña J; Serrano-Heras G; Montero JC; Corrales-Sánchez V; Pandiella A; Ocaña A
    Mol Cancer Ther; 2016 Aug; 15(8):1823-33. PubMed ID: 27256375
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Accurate programmed multifunctional nano-missiles for self-promoted deep delivery and synergistic cascade tumor therapy: Tactfully collaborating chemosynthesis with tumor microenvironment remodeling.
    Lu R; Wang S; Yang Z; Zhou L; Yang C; Wu Y
    Theranostics; 2022; 12(12):5299-5316. PubMed ID: 35910803
    [No Abstract]   [Full Text] [Related]  

  • 66. NIR-laser-triggered gadolinium-doped carbon dots for magnetic resonance imaging, drug delivery and combined photothermal chemotherapy for triple negative breast cancer.
    Jiang Q; Liu L; Li Q; Cao Y; Chen D; Du Q; Yang X; Huang D; Pei R; Chen X; Huang G
    J Nanobiotechnology; 2021 Mar; 19(1):64. PubMed ID: 33653352
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
    Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
    J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Platelet Membrane-Camouflaged Silver Metal-Organic Framework Biomimetic Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
    Liu H; Cai G; Yuan S; Zhou X; Gui R; Huang R
    Mol Pharm; 2024 Jul; 21(7):3577-3590. PubMed ID: 38857525
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Design and synthesis of dual BRD4/Src inhibitors for treatment of triple-negative breast cancer.
    Wang Y; Huang A; Chen L; Sun F; Zhao M; Zhang M; Xie Y; Xu S; Li M; Hong L; Li G; Wang R
    Eur J Med Chem; 2024 Jan; 264():116009. PubMed ID: 38070430
    [TBL] [Abstract][Full Text] [Related]  

  • 70. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
    Li Y; Xiao Y; Lin HP; Reichel D; Bae Y; Lee EY; Jiang Y; Huang X; Yang C; Wang Z
    Biomaterials; 2019 Jan; 188():160-172. PubMed ID: 30352320
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer.
    Zhao P; Xu Y; Ji W; Zhou S; Li L; Qiu L; Qian Z; Wang X; Zhang H
    J Nanobiotechnology; 2021 Jun; 19(1):181. PubMed ID: 34120612
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
    Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
    Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
    [TBL] [Abstract][Full Text] [Related]  

  • 73.
    Kasten BB; Oliver PG; Kim H; Fan J; Ferrone S; Zinn KR; Buchsbaum DJ
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29561763
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibiting the proliferation, migration and invasion of triple negative breast cancer cells through anti-tumor human serum albumin nanoparticles loading aziditaxel as a novel taxane derivative.
    Chen LQ; Zhang ZM; Huang W; Gao ZG; Fang WS; Jin MJ; Yu L
    Pharmazie; 2017 Mar; 72(3):152-160. PubMed ID: 29442050
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Photosensitive small extracellular vesicles regulate the immune microenvironment of triple negative breast cancer.
    Ding YN; Ding HY; Li H; Yang R; Huang JY; Chen H; Wang LH; Wang YJ; Hu CM; An YL; Zhang ZY; Yu WP; Tang QS; Shao GL
    Acta Biomater; 2023 Sep; 167():534-550. PubMed ID: 37302734
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
    Nieto-Jimenez C; Galan-Moya EM; Corrales-Sanchez V; Noblejas-Lopez MDM; Burgos M; Domingo B; Montero JC; Gomez-Juarez M; Picazo-Martinez MG; Esparis-Ogando A; Pandiella A; Ocaña A
    Cancer Lett; 2020 Oct; 491():50-59. PubMed ID: 32735909
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Overexpression of GLUT3 promotes metastasis of triple-negative breast cancer by modulating the inflammatory tumor microenvironment.
    Tsai TH; Yang CC; Kou TC; Yang CE; Dai JZ; Chen CL; Lin CW
    J Cell Physiol; 2021 Jun; 236(6):4669-4680. PubMed ID: 33421130
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.
    Pattarawat P; Wallace S; Pfisterer B; Odoi A; Wang HR
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):141-152. PubMed ID: 31865420
    [TBL] [Abstract][Full Text] [Related]  

  • 79. BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways.
    Zhang Y; Xu B; Shi J; Li J; Lu X; Xu L; Yang H; Hamad N; Wang C; Napier D; He S; Liu C; Liu Z; Qian H; Chen L; Wei X; Zheng X; Huang JA; Thibault O; Craven R; Wei D; Pan Y; Zhou BP; Wu Y; Yang XH
    Cell Oncol (Dordr); 2020 Dec; 43(6):1049-1066. PubMed ID: 33006750
    [TBL] [Abstract][Full Text] [Related]  

  • 80. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy.
    Cheng N; Bei Y; Song Y; Zhang W; Xu L; Zhang W; Yang N; Bai X; Shu Y; Shen P
    Biochem Pharmacol; 2021 Jan; 183():114298. PubMed ID: 33153969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.